Developmental Mechanisms of Human Structural Birth Defects (P01) | Apply Online

Frequently Asked Questions (FAQs)

What is this NIH funding opportunity (PAR-12-034) about?

PAR-12-034 is an NIH funding opportunity supporting Program Project (P01) grant applications aimed at uncovering the developmental and genetic mechanisms that cause human structural birth defects. The focus is on coordinated, team-based programs where basic developmental biology, translational research, and clinical investigation inform each other in a tightly integrated way.

Which NIH institutes or offices sponsor this opportunity?

This opportunity is sponsored by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) in partnership with the NIH Office of Dietary Supplements (ODS).

What grant mechanism does this use?

The mechanism is the NIH Program Project Grant (P01), designed for multi-project, multi-investigator programs with a unifying central theme and substantial scientific synergy across projects.

What is the core scientific goal of the program?

The program goal is to explain why structural congenital malformations occur by linking mechanistic developmental and genetic insights (often from animal models) with human clinical and translational evidence (such as patient phenotyping, cohorts, genomics, biomarkers, or intervention-oriented studies) in a coordinated pipeline.

What does NIH mean by a "genuinely interactive and synergistic" P01 in this announcement?

It means the three component projects are expected to be interdependent and coordinated so that the combined work produces outcomes that would be difficult to achieve through separate, disconnected projects. Reviewers would expect cross-project integration, shared goals, and clear evidence that findings in one component meaningfully drive or refine work in the others.

How many research projects must be included in the P01?

Each funded P01 under this announcement must contain exactly three component research projects.

Are shared cores allowed or required?

Shared cores are allowed as needed. Cores can provide common services, resources, or infrastructure used by the component projects to support integration and efficiency.

Are there required types of projects within the three components?

Yes. Within the three projects, the program must include at least one basic research project using an animal model system and at least one project that is clinical or translational in nature.

Does the announcement require cross-species relevance between animal and human studies?

Yes. The targeted structural defect(s) must be meaningfully comparable between animals and humans, and applicants are expected to justify relevance through genotype, mechanism, biology, or phenotype. The rationale should show that the animal model reflects key aspects of the human condition and that the human work is aligned closely enough to support cross-species interpretation.

Can the three projects cover different birth defects, as long as they are all structural malformations?

No. The three projects cannot be a loose collection of birth defect studies. They must share a single central theme, objective, or focus targeting a specific structural malformation or a defined class of anomalies.

What types of scientific topics are considered relevant to the basic developmental biology side?

The announcement highlights areas such as gene function, signaling pathways, morphogenesis, and nutrient-related influences on development, as long as they are tied to understanding the mechanisms underlying structural malformations and integrated with aligned human studies.

What kinds of human or patient-based work fit the clinical/translational requirement?

Examples described include clinical phenotyping, patient cohorts, genomics, and biomarker- or intervention-oriented studies, provided they connect directly to the same malformation theme and enable coordinated interpretation alongside the animal-model work.

Is this opportunity focused on congenital structural malformations specifically, or broader pediatric conditions?

It is focused on congenital structural malformations specifically, emphasizing developmental biology and genetic underpinnings rather than unrelated pediatric conditions.

What is the CFDA number and domain listed for this opportunity?

The opportunity is categorized in the health domain under CFDA 93.865.

Is cost sharing or matching required?

No. The announcement specifies that there is no cost sharing or matching requirement.

Is PAR-12-034 currently open for new submissions?

No. The announcement is archived. It was posted in November 2011, lists an original closing date in January 2015, and an archive date in August 2013. Based on the provided information, it is not currently open for new submissions under this specific announcement.

Even though it is archived, what does PAR-12-034 illustrate about NIH expectations for a birth-defects-focused P01?

It provides a clear template emphasizing a tightly constrained structure (exactly three integrated projects), shared infrastructure via cores as needed, required inclusion of both animal-model basic research and human clinical/translational work, and a strong justification for synergy around one structural malformation theme.

What types of U.S. organizations are eligible to apply?

Eligibility is broad across many U.S.-based organizations, including public and private institutions of higher education; nonprofit organizations (with and without 501(c)(3) status); for-profit entities (including small businesses, which are explicitly listed); and government entities such as state, county, city/township, and special district governments. Tribal governments and tribally controlled institutions are also included.

Are mission-focused institution types (such as HBCUs or Hispanic-serving institutions) eligible?

Yes. The announcement notes eligibility for institution types including HBCUs, Hispanic-serving institutions, Alaska Native and Native Hawaiian serving institutions, and faith-based or community-based organizations.

Can non-U.S. (foreign) institutions apply directly?

No. Non-U.S. (foreign) institutions and non-U.S. components of U.S. organizations are not eligible to apply directly under this announcement.

Are any international activities allowed at all?

Yes. While foreign institutions cannot apply directly, foreign components (as defined by NIH policy) are allowed. This generally refers to discrete international collaborations or activities that can be included when justified and compliant with NIH rules.

What is the main structural constraint used to manage costs and keep the program integrated?

The defining structural constraint is that the P01 must include exactly three component research projects, with shared cores included only as needed. This design is intended to manage costs while keeping the program tightly linked and coordinated.

What should applicants be prepared to demonstrate to meet the integration expectations?

Applicants should be prepared to show that all three projects align around a single malformation theme, that at least one project is animal-model basic research and at least one is clinical/translational, and that there is a convincing cross-species rationale enabling findings to be interpreted together through shared mechanisms, genotypes, biology, or phenotypes.

What kind of team is this opportunity designed for?

It is designed for institutions that can assemble a coordinated, multidisciplinary team capable of combining animal-model developmental biology with clinically grounded human studies to explain the mechanisms of structural malformations and translate insights across species.